Phaseline

Targets › FOLR1

FOLR1 (Folate receptor alpha): drug programs, companies and trials

19 programs from 16 companies in 34 trials: 16 Phase 1, 14 Phase 2, 3 Phase 3, 1 Phase 4; Oncology; next expected readout Nov 2026.

Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. (UniProt, P15328)

Open in Phaseline: the race on FOLR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cedars-Sinai Medical CenterCYTALUX™ (pafolacianine)
Folate receptor-targeted fluorescent imaging agent (near-infrared fluorophore conjugate)
FOLR1Phase 4Gastrointestinal CancerAug 2027
AbbVieMirvetuximab Soravtansine
Folate receptor alpha binding agent; Tubulin inhibitor
FOLR1, TubulinPhase 3Ovarian Cancer; High Grade Ovarian Cancer; Recurrent Ovarian Cancer; Advanced High-Grade Epithelial Ovarian Cancer …Nov 2026
Mayo ClinicPafolacianine Sodium
Fluorescent imaging agent targeting folate receptor alpha (FOLR1)
FOLR1Phase 3Childhood Malignant Solid NeoplasmMay 2027
AstraZenecaAZD5335
Anti-FRα antibody-drug conjugate
FOLR1Phase 3Epithelial Ovarian Cancer; Fallopian Tube CancerOct 2027
AbbVieIMGN151
anti-FOLR1 antibody-drug conjugate
FOLR1Phase 2Gynecologic Cancers; Endometrial CancerFeb 2027
CSPC Megalith BiopharmaceuticalSYS6041
anti-FOLR1 antibody-drug conjugate
FOLR1Phase 2Ovarian Cancer; Advanced Solid TumorsMar 2027
John WatersCYTALUX (pafolacianine)
Folate analog ligand conjugated with indole cyanine green-like dye for near-infrared fluor
FOLR1Phase 2Esophageal CancerDec 2027
Mayo ClinicMulti-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Folate receptor alpha-loaded dendritic cell vaccine
FOLR1Phase 2Advanced Fallopian Tube Carcinoma; Fallopian Tube CarcinosarcomaApr 2029
Academic and Community Cancer Research UnitedMulti-epitope Folate Receptor Alpha Peptide Vaccine
Multi-epitope peptide vaccine targeting folate receptor alpha
FOLR1Phase 2Bilateral Breast Carcinoma–
Beijing BiotechEB-NK-MF CAR-NK cells
Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit
MSLN, FOLR1, MUC16, TROP2Phase 1Advanced Solid Tumors; Epithelial Ovarian CancerFeb 2027
EpsilogenMOv18 IgE
Anti-folate receptor alpha (FRα) monoclonal antibody of the IgE class
FOLR1Phase 1Advanced Ovarian CancerMar 2027
TakedaMirvetuximab Soravtansine (TAK-853)
Folate receptor alpha binding agent; Tubulin inhibitor
FOLR1, TubulinPhase 1Ovarian CancerMar 2027
Fred Hutchinson Cancer CenterFOLR1 CAR T-cells
Anti-FOLR1 chimeric antigen receptor T-cell therapy
FOLR1Phase 1Recurrent Childhood Acute Myeloid LeukemiaOct 2027
Changchun GeneScience PharmaceuticalGenSci140
Folate receptor alpha (FRα) targeting agent for FRα-positive advanced solid tumors
FOLR1Phase 1Advanced Solid TumorsMar 2028
Fred Hutchinson Cancer CenterFH-FOLR1 ST CAR T-cells
anti-FOLR1 CAR-T cell therapy
FOLR1Phase 1Advanced OsteosarcomaJan 2029
Phrontline BiopharmaTJ102
CDH6/FRα directed antibody-drug conjugate with dual payloads
CDH6, FOLR1Phase 1Ovarian CancerSep 2029
Institute of Cancer Research, United KingdomIdetrexed
Folate receptor-targeted thymidylate synthase inhibitor
TYMS, FOLR1Phase 1High Grade Serous Ovarian CancerDec 2029
EisaiFarletuzumab
Folate receptor alpha inhibitor
FOLR1Phase 1Solid TumorAug 2030
Ann & Robert H Lurie Children's Hospital of ChicagoCytalux
Folate analog-fluorophore conjugate targeting folate receptor
FOLR1Phase 1Osteosarcoma–

Conditions

Ovarian Cancer (6) Epithelial Ovarian Cancer (4) Advanced Solid Tumors (3) Endometrial Cancer (3) Advanced Ovarian Cancer (1) Childhood Malignant Solid Neoplasm (1) Advanced Fallopian Tube Carcinoma (1) Fallopian Tube Carcinosarcoma (1) Recurrent Childhood Acute Myeloid Leukemia (1) Osteosarcoma (1) Esophageal Cancer (1) Solid Tumor (1)

Modalities

small molecule (8), mixed (8), antibody (2), protein or peptide (1)

Companies

Mayo Clinic (2) Fred Hutchinson Cancer Center (2) AbbVie (2) Epsilogen (1) Phrontline Biopharma (1) Beijing Biotech (1) Ann & Robert H Lurie Children's Hospital of Chicago (1) John Waters (1) Eisai (1) Changchun GeneScience Pharmaceutical (1) Academic and Community Cancer Research United (1) Takeda (1) CSPC Megalith Biopharmaceutical (1) AstraZeneca (1) Cedars-Sinai Medical Center (1) Institute of Cancer Research, United Kingdom (1)

Related targets

Tubulin (2) CDH6 (1) MSLN (1) MUC16 (1) TROP2 (1) TYMS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.